Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9494 | 0.75 | RAB9A (0.47) | NOTUMPTK2 | |
| SCHEMBL12419306 | 0.69 | NOTUM (0.33) | MTNR1AMTNR1BNOTUM | |
| SCHEMBL23997494 | 0.68 | HRH3 (0.38) | MTNR1AMTNR1B | |
| SCHEMBL12419303 | 0.67 | TP53 (0.44) | ENPP2 | |
| SCHEMBL17994177 | 0.65 | NOTUM (0.48) | NOTUM | |
| SCHEMBL23997326 | 0.65 | RAB9A (0.42) | MTNR1AMTNR1BPTK2 | |
| Ethoxycarbonyl Group SCHEMBL28264125 | 0.64 | SMN1; SMN2 (0.35) | NOTUMPTK2 | |
| SCHEMBL27458837 | 0.64 | NOTUM (0.44) | NOTUM | |
| SCHEMBL14379304 | 0.63 | ENPP2 (0.36) | ENPP2 | |
| SCHEMBL18462192 | 0.63 | CES1 (0.50) | MTNR1AMTNR1BNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-8957049-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | MTNR1A 1144/4885MTNR1B 551/4885NOTUM 123/4885 |
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | MTNR1A 1144/4885MTNR1B 551/4885NOTUM 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.